Share this article
REHOVOT and JERUSALEM
, Israel, April 6, 2021 /PRNewswire/ -- MyBiotics Pharma Ltd. http://biomx.com/, a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have entered into a research collaboration and licensing agreement for the identification of microbiome-based therapeutics that will enhance the response to and reduce adverse effects of anti-PD-1 and anti-PD-L1 in melanoma patients.
The collaboration will combine Hadassah's knowhow and expertise in immunotherapy treatment of melanoma patients with MyBiotics' proprietary microbiome technologies enabling development of novel therapeutics. The two-year joint research project will be conducted by researchers from MyBiotics together with a team of researchers at Hadassah Cancer Research Institute headed by Prof. Michal Lotem, MD., Head of the Center for Melanoma and Cancer Immunotherapy, Department of Oncology at Hadassah Medical Center. It will be funded by MyBiotics, which has an exclusive license for all data and inventions stemming from the collaboration.
Related Keywords
Jerusalem ,Israel General ,Israel ,Rehovot ,Hamerkaz ,Tsipi Haitovsky ,Itamar Raz ,Michal Lotem ,Mybiotic Superdonor ,Kfir Umansky ,David Daboush ,Mybiotics Pharma ,Hadar Elboim ,Hadasit Medical Research Services ,Linkedin ,Hadassah Medical Center ,Mybiotics Pharma Ltd ,Hadassah Medical Organization ,Department Of Oncology At Hadassah Medical Center ,Hadassah Cancer Research Institute ,Development Ltd ,Head Of The Center ,Prnewswire Mybiotics Pharma Ltd ,Biotics Pharma ,Hadassah Medical ,Prof Michal Lotem ,Chief Operation Officer ,ஏருசலேம் ,இஸ்ரேல் ஜநரல் ,இஸ்ரேல் ,தாமரை ர்யாஸ் ,சென்டர் ,ஹடாஸா மருத்துவ மையம் ,ஹடாஸா மருத்துவ ஆர்கநைஸேஶந் ,துறை ஆஃப் புற்றுநோயியல் இல் ஹடாஸா மருத்துவ மையம் ,ஹடாஸா புற்றுநோய் ஆராய்ச்சி நிறுவனம் ,வளர்ச்சி லிமிடெட் ,தலை ஆஃப் தி மையம் ,ஹடாஸா மருத்துவ ,தலைமை செயல்பாடு அதிகாரி ,
comparemela.com © 2020. All Rights Reserved.